

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- | | |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

During scoping the company raised that the prevalence of NPC can be higher in some ethnic minority groups such as Southern Chinese, Northern African, and Alaskan origin.

- | | |
|----|------------------------------------------------------------------------------------------------------------------|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|----|------------------------------------------------------------------------------------------------------------------|

An impact of the appraisal will be considered by committee.

- | | |
|----|---------------------------------------------------------------------------------------|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---------------------------------------------------------------------------------------|

No.

- | | |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 4. | Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made? |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

No additional stakeholders have been identified during the scoping process.

Approved by Associate Director (name): Ross Dent

Date: 16/12/2025